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Background
KS is a disease of multifocal vascular proliferation.
Matrix metalloproteinases (MMPs) and type I collagen
play critical roles in angiogenesis and are potential
targets. Halofuginone (Tempostatin™), a synthetic quina-
zolinone alkaloid derivative, induced anti-angiogenic,
anti-metastatic and anti-proliferative effects in preclini-
cal studies. It inhibits several essential stages of angio-
genesis: endothelial cell proliferation, MMP2 expression,
BM invasion, ECM deposition by newly formed vessels,
synthesis of type I collagen during angiogenic sprouting,
and bFGF-induced neovascularization. These data
suggested that halofuginone might have activity in KS.
Methods
The AMC developed a novel trial design with a blinded
intra-patient vehicle control. Halofuginone was supplied
by Collgard Biopharmaceuticals Ltd (Atlanta, GA) to the
NCI-DCTD under a CRADA as a 0.01% w/w ointment.
Twelve KS lesions were divided into two groups of six,
designated Group A and Group B. Tubes designated A
and B containing either halofuginone or matching placebo
ointment were supplied in a blinded fashion. Ointment A
was applied to Group A lesions and ointment B to Group
B lesions twice daily. Lesion response was assessed every
4 weeks for Group A and Group B lesions individually,
and global response assessed both treated and untreated
disease. Tumor biopsies obta i n e da tb a s e l i n ea n df r o m
both Group A and B lesions during treatment were stu-
died for expression of type I collagen by ISH and of
MMP2 and VEGF by IHC. A patient subset had blood
sampling after 8 weeks to evaluate systemic absorption.
Results
Twenty-three patients were treated. Median CD4 count
was 322 (2-693); 68% had undetectable HIV RNA. Treat-
ment was well tolerated. Of 14 patients who completed
12 weeks of treatment, 26% (95% CI, 10%-48%) showed
partial response in halofuginone-treated lesions and 17%
in placebo-treated lesions (95% CI, 5%-39%), (P=0.689).
Global response was 30% (95% CI, 13%-53%). None of
10 subjects showed detectable blood levels. Type 1 col-
lagen message decreased significantly in halofuginone-
treated lesions at week 4, whereas vehicle-treated lesions
showed no change. VEGF protein expression decreased
significantly in vehicle-treated lesions at week 4, whereas
halofuginone-treated lesions showed no change. There
were no differences in levels of MMP2 or VEGF protein
between halofuginone- and vehicle-treated lesions.
No changes in HIV RNA levels or CD4 counts were
observed.
Conclusion
Although topical halofuginone appears ineffective for KS
treatment, this study presents a novel design that could
be applied to future studies using the patient as his own
control to test a topical, non-absorbed agent.
*Correspondence: krowns@mskcc.org
1Department of Medicine, Memorial Sloan-Kettering Cancer Center,
New York, NY, USA
Full list of author information is available at the end of the article
Krown et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A62
http://www.infectagentscancer.com/content/5/S1/A62
© 2010 Krown et al; licensee BioMed Central Ltd.Acknowledgements
This work was supported by UO1 CA121947.
This article has been published as part of Infectious Agents and Cancer
Volume 5 Supplement 1, 2010: Proceedings of the 12
th International
Conference on Malignancies in AIDS and Other Acquired
Immunodeficiencies (ICMAOI). The full contents of the supplement are
available online at http://www.biomedcentral.com/1750-9378/5?issue=S1.
Author details
1Department of Medicine, Memorial Sloan-Kettering Cancer Center,
New York, NY, USA.
2Department of Cancer Biology, Vanderbilt-Ingram
Cancer Center, Nashville, TN, USA.
3Department of Biostatistics, University of
Arkansas Medical School, Little Rock, AR, USA.
4Departments of Medicine and
Pharmacology, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
5Ireland Cancer Center, Case Western Reserve University, Cleveland, OH, USA.
Published: 11 October 2010
doi:10.1186/1750-9378-5-S1-A62
Cite this article as: Krown et al.: Phase II AIDS Malignancy Consortium
(AMC) trial of topical halofuginone in AIDS-associated Kaposi’s sarcoma
(KS): clinical and biological effects using a novel intra-patient control
design. Infectious Agents and Cancer 2010 5(Suppl 1):A62.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Krown et al. Infectious Agents and Cancer 2010, 5(Suppl 1):A62
http://www.infectagentscancer.com/content/5/S1/A62
Page 2 of 2